Introduction
Asthma is a serious public health problem throughout the world, affecting people of all ages. It is estimated that around 300 million people worldwide currently have asthma. Diagnosing asthma at an earlier stage and instituting appropriate therapy decreases the socio economic burden for asthmatics and significantly enhances the quality of the patient's life, as medications continue to be the mainstay of treatment and contributes to a major chunk of the cost involved.
The total magnesium content of our body is about 25 gm (1000mmol). 50% of this is present in bones and only about 1% is present in the extracellular fluid, the remaining being intracellular. Approximately 30% of serum magnesium is bound to albumin. Magnesium deficiency has been associated with a number of chronic diseases like diabetes mellitus, hypertension and dyslipidemia. Therapeutically, magnesium is found to be useful in acute coronary events, preeclampsia, eclampsia and ventricular tachyarrythmias. In the case of acute asthma both intravenous and inhaled magnesium can be used.
International guidelines recommend the use of intravenous Mgso4 in case of acute severe asthma, especially if FEV1 levels are between 25 to 30 % of predicted values at presentation, or when there is poor response to short acting beta 2 agonists. The possible mechanisms of action of magnesium in bronchial asthma are inhibition of vascular and bronchial smooth muscle contraction, inhibition of release of acetylcholine from cholinergic nerves, enhancement of nitric oxide and prostaglandin generation and smooth muscle stabilization. As an intracellular cation, magnesium is involved in the regulation of bronchial smooth muscle tone, mast cell stabilization, neuromuscular activity and respiratory muscle function. Low intracellular magnesium concentration may promote the hyper responsiveness of airways in asthmatic patients. International guidelines recommend the use of magnesium through intravenous route for treating acute severe exacerbations of asthma unresponsive to other standard medications. 
II. Aim Of Study
To assess the levels of serum magnesium in patients with chronic stable asthma and to find out any correlation between the severity of asthma and hypomagnesemia.
III. Materials And Methods
This study was undertaken with the aim to determine serum magnesium levels in patients with chronic stable asthma and to determine whether low levels of magnesium was associated with disease severity and higher incidence of hospitalizations and to assess whether therapeutic drugs used in the management of asthma have an effect on magnesium levels.
IV. Study population:
This study was conducted at Government Rajaji Hospital, Madurai on a total of 150 subjects of age more than 12 years who attended the outpatient department: of whom 50 were apparently healthy and served as controls. 
Data collection
For the 100 chronic asthmatic patients who were included in the study, detailed history was taken regarding symptoms, duration of asthma, previous exacerbations, seasonal variation, medications ( use of SABA, LABA, methyl xanthines,ICS, leucotriene inhibitors ) ,alcoholism, diabetes, cardiac illness, chronic kidney disease and diarrhea as per the proforma. It was followed by physical and respiratory system examination. Pulmonary function test using spirometry has been done. Chest x ray has been taken .Blood samples were collected for measurement of serum magnesium. Blood urea, serum potassium, serum albumin levels were estimated. Calorimetric method was done for the quantitative assessment of magnesium in the serum of the study and control population.
V. Results
Severity of Asthma was assesd based on FEV 1 /FVC ratio in the 100 patients with asthma .Among the cases, majority (33%) had mild asthma while very severe disease was present only in 13% .Moderate and severe degrees were almost equally distributed,29 % & and 25 % respectively . 
Comments:
1) The mean serum magnesium level of the study group was much lower than the mean serum magnesium level of the control group and this difference was statistically significant. 2) Hence, patients with asthma had a lower level of serum magnesium level when compared to the healthy subjects in the control group. Chi square p value: <0.001 Comments: 1) out of 36 % of hypomagnesemia in total study population including control and patients , 34% of hypomagnesemia seen in the patient group and while hypomagenesemia was only 4% in the controls.
2)The difference in prevalence of hypomagnesaemia between study and control group was found to be statistically significant. 
The mean magnesium value in cases was 1.557 and in the control was 2.034 and this was significantly lower resulting from a 34% prevalence of hypomagnesemia in cases as opposed to just 4% in controls. Chi-square p value: <0.001
The prevalence of hypomagnesaemia was increasing with increasing severity of disease and this difference across various levels of severity was statistically significant. Comments: 1) When compared to subjects with mild asthma, subjects with moderate, severe and very severe asthma had higher prevalence of hypomagnesaemia (OR: 2.7, 6.6, and 24.1, respectively).
2) The higher odds ratio for subjects with severe and very severe asthma when compared to mild disease was statistically significant but it was not significant in case of moderate vs mild disease.
VI. Discussion
A high prevalence of low plasma magnesium concentrations among patients with bronchial asthma has been reported in various studies and there is a possible association of hypomagnesemia with the severity of bronchial asthma.However, some workers have also reported normal values in asthma. Hence we have attempted to assess the presence of hypomagnesemia in chronic stable asthma patients.In our study, the prevalence of low serum magnesium concentrations in chronic stable asthma patients was 34%. This conforms to the reported prevalence of hypomagnesemia in chronic stable asthmatics in several studies, which ranged from 26 to 40%. "Khosrow Agin" et alwho studied asthmatic patients attending pulmonary medicine department of Loghmann Hakim Hospital at Tehran -Iran, described 40.5% prevalence of hypomagnesemia in patients with chronic stable asthma.The figure was 27% in the study by "O.S.B .Aloamoudi" et al., done at the Medicine department of King AbdulAziz University hospital, Jeddah in Kingdom of Saudi Arabia
VII. Conclusion
There is presence of hypomagnesemia in chronic stable asthma and the prevalence was found to be 34%. There is a significant difference in magnesium levels between patients with asthma compared to normal population. Mean magnesium in the study group was 1.557 and in controls it was 2.034 and this was statistically significant (p value < 0.001) .It was found that hypomagnesemia has no significant correlation with age , gender or duration of asthma.. Hypomagnesemia is significantly associated with severity of asthma and is more prevalent in very severe asthma (p value < 0.001). Magnesium rich foods may be encouraged for asthmatic patients . The cause of hypomagnesemia in asthma and role of magnesium supplementation in asthmatics is an important field warranting further research. 
